New malaria vaccine vivaxin enters first human tests
NCT ID NCT07172724
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 30 times
Summary
This early-stage study tests a new vaccine called Vivaxin, designed to prevent malaria caused by the Plasmodium vivax parasite. Researchers will give the vaccine to 48 healthy adults who have never had malaria to check if it is safe and triggers a strong immune response. The study is placebo-controlled and double-blind, meaning neither participants nor doctors know who gets the real vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VIVAX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centro de Pesquisas Clínicas (CPC) do Hospital das Clínicas (HC) da UFMG/ Filial Ebserh
Belo Horizonte, Minas Gerais, 30130-100, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.